Repros Therapeutics (RPRX) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Repros Therapeutics Inc.® Reports Fourth Quarter and Year End 2015 Financial Results
March 14, 2016 9:15 AM EDTTHE WOODLANDS, Texas, March 14, 2016 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced financial results for the fourth quarter and year ended December 31, 2015.
Financial Results
Net loss for the three month period ended December 31, 2015, was ($6.3) million or ($0.26) per share as compared to a net loss of ($7.4) million or ($0.31) per share for the same period in 2014. The net loss for the year ended December 31, 2015, was ($29.2) million or ($1.20) per share as compared to a net loss of ($32.5) million or ($1.39) per share for 2014. The decreases... More
